MDR Amending Regulation Improves Communication and Workflow But Thorny Issues Remain
Executive Summary
In the EU, the amending regulation to the MDR is not creating as many waves as the amending regulation to the IVDR did. The reasons are many. But this is good news for the medtech industry, as is a general uptick in purposeful communication.
You may also be interested in...
How Notified Bodies And Manufacturers Are Attempting To Navigate Uncertainty Under The IVDR
There are still several missing key elements needed for the implementation of the EU’s IVD Regulation. Three key experts focused on how to move forward, particularly with the highest risk, class D, IVDs.
No Valid Excuses For Manufacturers To Delay IVD Regulations Applications, Experts Warn
Too many perceived factors are being used by IVD manufacturers to unnecessarily delay progressing their applications under the IVD Regulation with potentially serious consequences. Three well-known medtech regulatory experts explain why manufacturers must act now.
Optimizing EU Medtech Regulatory Governance And Innovation: First Workshop Shapes Future Study
Work related to the European Commission’s promise to assess the impact of the Medical Device Regulation, including its impact on innovation, is starting to take shape.